These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33843081)

  • 1. Stem cell concepts in myelodysplastic syndromes: lessons and challenges.
    Woll PS; Jacobsen SEW
    J Intern Med; 2021 May; 289(5):650-661. PubMed ID: 33843081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.
    Nilsson L; Astrand-Grundström I; Anderson K; Arvidsson I; Hokland P; Bryder D; Kjeldsen L; Johansson B; Hellström-Lindberg E; Hast R; Jacobsen SE
    Blood; 2002 Jul; 100(1):259-67. PubMed ID: 12070035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.
    Woll PS; Kjällquist U; Chowdhury O; Doolittle H; Wedge DC; Thongjuea S; Erlandsson R; Ngara M; Anderson K; Deng Q; Mead AJ; Stenson L; Giustacchini A; Duarte S; Giannoulatou E; Taylor S; Karimi M; Scharenberg C; Mortera-Blanco T; Macaulay IC; Clark SA; Dybedal I; Josefsen D; Fenaux P; Hokland P; Holm MS; Cazzola M; Malcovati L; Tauro S; Bowen D; Boultwood J; Pellagatti A; Pimanda JE; Unnikrishnan A; Vyas P; Göhring G; Schlegelberger B; Tobiasson M; Kvalheim G; Constantinescu SN; Nerlov C; Nilsson L; Campbell PJ; Sandberg R; Papaemmanuil E; Hellström-Lindberg E; Linnarsson S; Jacobsen SE
    Cancer Cell; 2014 Jun; 25(6):794-808. PubMed ID: 24835589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level.
    Nilsson L; Astrand-Grundström I; Arvidsson I; Jacobsson B; Hellström-Lindberg E; Hast R; Jacobsen SE
    Blood; 2000 Sep; 96(6):2012-21. PubMed ID: 10979941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes.
    Pang WW; Pluvinage JV; Price EA; Sridhar K; Arber DA; Greenberg PL; Schrier SL; Park CY; Weissman IL
    Proc Natl Acad Sci U S A; 2013 Feb; 110(8):3011-6. PubMed ID: 23388639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting stem cells in myelodysplastic syndromes and acute myeloid leukemia.
    Woll PS; Yoshizato T; Hellström-Lindberg E; Fioretos T; Ebert BL; Jacobsen SEW
    J Intern Med; 2022 Aug; 292(2):262-277. PubMed ID: 35822488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.
    Dimitriou M; Woll PS; Mortera-Blanco T; Karimi M; Wedge DC; Doolittle H; Douagi I; Papaemmanuil E; Jacobsen SE; Hellström-Lindberg E
    Oncotarget; 2016 Nov; 7(45):72685-72698. PubMed ID: 27683035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cytokines in leukemic type growth of myelodysplastic CD34+ cells.
    Sawada K; Ieko M; Notoya A; Tarumi T; Koizumi K; Kitayama S; Nishio H; Fukada Y; Yasukouchi T; Yamaguchi M; Katoh S; Koike T
    Blood; 1996 Jul; 88(1):319-27. PubMed ID: 8704190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Architectural and functional heterogeneity of hematopoietic stem/progenitor cells in non-del(5q) myelodysplastic syndromes.
    Chesnais V; Arcangeli ML; Delette C; Rousseau A; Guermouche H; Lefevre C; Bondu S; Diop M; Cheok M; Chapuis N; Legros L; Raynaud S; Willems L; Bouscary D; Lauret E; Bernard OA; Kosmider O; Pflumio F; Fontenay M
    Blood; 2017 Jan; 129(4):484-496. PubMed ID: 27856460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.
    Will B; Zhou L; Vogler TO; Ben-Neriah S; Schinke C; Tamari R; Yu Y; Bhagat TD; Bhattacharyya S; Barreyro L; Heuck C; Mo Y; Parekh S; McMahon C; Pellagatti A; Boultwood J; Montagna C; Silverman L; Maciejewski J; Greally JM; Ye BH; List AF; Steidl C; Steidl U; Verma A
    Blood; 2012 Sep; 120(10):2076-86. PubMed ID: 22753872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stem and progenitor cell alterations in myelodysplastic syndromes.
    Shastri A; Will B; Steidl U; Verma A
    Blood; 2017 Mar; 129(12):1586-1594. PubMed ID: 28159737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal CD25 expression on hematopoietic cells in myelodysplastic syndromes.
    Liu P; Jiang H; Che M; Fu R; Wang H; Li L; Zhang W; Tao J; Gao S; Shao Z
    Leuk Res; 2018 Apr; 67():12-16. PubMed ID: 29407181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
    Ganan-Gomez I; Yang H; Ma F; Montalban-Bravo G; Thongon N; Marchica V; Richard-Carpentier G; Chien K; Manyam G; Wang F; Alfonso A; Chen S; Class C; Kanagal-Shamanna R; Ingram JP; Ogoti Y; Rose A; Loghavi S; Lockyer P; Cambo B; Muftuoglu M; Schneider S; Adema V; McLellan M; Garza J; Marchesini M; Giuliani N; Pellegrini M; Wang J; Walker J; Li Z; Takahashi K; Leverson JD; Bueso-Ramos C; Andreeff M; Clise-Dwyer K; Garcia-Manero G; Colla S
    Nat Med; 2022 Mar; 28(3):557-567. PubMed ID: 35241842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do preclinical studies suggest that CD99 is a potential therapeutic target in acute myeloid leukemia and the myelodysplastic syndromes?
    Tavakkoli M; Chung SS; Park CY
    Expert Opin Ther Targets; 2018 May; 22(5):381-383. PubMed ID: 29637789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysfunctional bone marrow endothelial progenitor cells are involved in patients with myelodysplastic syndromes.
    Xing T; Lyu ZS; Duan CW; Zhao HY; Tang SQ; Wen Q; Zhang YY; Lv M; Wang Y; Xu LP; Zhang XH; Huang XJ; Kong Y
    J Transl Med; 2022 Mar; 20(1):144. PubMed ID: 35351133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cell origin of myelodysplastic syndromes.
    Elias HK; Schinke C; Bhattacharyya S; Will B; Verma A; Steidl U
    Oncogene; 2014 Oct; 33(44):5139-50. PubMed ID: 24336326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis.
    Walenda T; Stiehl T; Braun H; Fröbel J; Ho AD; Schroeder T; Goecke TW; Rath B; Germing U; Marciniak-Czochra A; Wagner W
    PLoS Comput Biol; 2014 Apr; 10(4):e1003599. PubMed ID: 24763223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonality in the myelodysplastic syndromes.
    Boultwood J; Wainscoat JS
    Int J Hematol; 2001 Jun; 73(4):411-415. PubMed ID: 11503954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
    Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
    Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanism of microRNA involvement in genesis of myelodysplastic syndrome and its transformation to acute myeloid leukemia.
    Liao R; Xu Y; Chen M; Chen X; Zhan X; Sun J
    Hematology; 2013 Jul; 18(4):191-7. PubMed ID: 23321417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.